X

Drug Profile

Research programme: obesity therapies - Biocon

Alternative Names: NLC-002

Latest Information Update: 10 Apr 2007

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biocon
Class
Mechanism of Action Cholecystokinin stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Obesity

Most Recent Events

27 Feb 2004 NLC 002 is available for partnering for obesity worldwide (2nd Annual BioPartnering North America Conference (BPN-2004) (http://www.nobexcorp.com)
24 Sep 2002 Lead compound of the programme has been identified as NLC 002
19 Mar 2002 Preclinical trials in Obesity in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com